{"id":58679,"date":"2026-03-03T16:22:39","date_gmt":"2026-03-03T08:22:39","guid":{"rendered":"https:\/\/flcube.com\/?p=58679"},"modified":"2026-03-03T16:22:40","modified_gmt":"2026-03-03T08:22:40","slug":"microport-endovasculars-hector-wins-fda-breakthrough-designation-multi-branch-stent-graft-targets-complex-aortic-arch-lesions","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=58679","title":{"rendered":"MicroPort Endovascular’s Hector Wins FDA Breakthrough Designation \u2013 Multi\u2011Branch Stent Graft Targets Complex Aortic Arch Lesions"},"content":{"rendered":"\n

Shanghai MicroPort Endovascular MedTech Co., Ltd (SHA:\u202f688016<\/a>)<\/strong> announced that its Hector thoracic aortic multi\u2011branch stent graft system<\/strong> has received Breakthrough Device Designation (BDD)<\/strong> from the U.S. Food and Drug Administration (FDA)<\/strong>. The innovative device enables simultaneous endovascular reconstruction<\/strong> of the aorta and all three supra\u2011aortic branches<\/strong>\u2014addressing a critical unmet need<\/strong> in the minimally invasive treatment of complex thoracic aortic lesions involving the aortic arch<\/strong>.<\/p>\n\n\n\n

Regulatory Milestone<\/h2>\n\n\n\n
Item<\/th>Detail<\/th><\/tr><\/thead>
Company<\/strong><\/td>Shanghai MicroPort Endovascular MedTech Co., Ltd (SHA:\u202f688016)<\/td><\/tr>
Product<\/strong><\/td>Hector<\/td><\/tr>
Device Class<\/strong><\/td>Thoracic aortic multi\u2011branch stent graft system<\/td><\/tr>
Regulatory Body<\/strong><\/td>U.S. Food and Drug Administration (FDA)<\/td><\/tr>
Designation<\/strong><\/td>Breakthrough Device Designation (BDD)<\/td><\/tr>
Indication<\/strong><\/td>Thoracic aortic lesions involving all three branches of the aortic arch<\/td><\/tr>
Procedure Type<\/strong><\/td>Minimally invasive interventional treatment<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Device Innovation<\/h2>\n\n\n\n
Feature<\/th>Hector Advantage<\/th>Clinical Impact<\/th><\/tr><\/thead>
Multi\u2011Branch Design<\/strong><\/td>Simultaneous reconstruction of aorta + 3 supra\u2011aortic branches<\/td>Single\u2011procedure complete arch repair<\/td><\/tr>
Minimally Invasive<\/strong><\/td>Endovascular delivery vs. open surgical repair<\/td>Reduced surgical trauma, faster recovery, lower morbidity<\/td><\/tr>
Aortic Arch Extension<\/strong><\/td>Extends endovascular therapy to entire aortic arch<\/td>Addresses previously “inoperable” complex arch lesions<\/td><\/tr>
Comprehensive Option<\/strong><\/td>Complete surgical solution via interventional approach<\/td>Fills critical gap between simple stent grafts and high\u2011risk open surgery<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Strategic Implications<\/h2>\n\n\n\n